

## **Solving Complex Pharmaceutical Challenges**

### **Hovione, Global CDMO Company**

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel.

With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.

The company is especially renowned for its global leadership in pharmaceutical spray drying, a technology critical for enhancing the solubility and bioavailability of oral medicines, and collaborates with 18 of the top 20 global pharmaceutical companies contributing significantly to the approval of 2% to 10% of new drugs by the U.S. Food and Drug Administration (FDA) each year over the past eight years.

Additionally, Hovione has established continuous tableting technology, an advanced, agile, and secure platform that accelerates the transition from powder to tablet, ensuring robust product quality and consistent supply through optimized process control strategies and unified equipment for both development and commercial production.

Operating manufacturing sites in Portugal (Loures), the USA (New Jersey), Ireland (Cork), and Macau, Hovione ensures adherence to rigorous international standards and regulatory compliance. Its stringent reflect the company's deep commitment to quality, safety, and environmental sustainability. Currently, Hovione is expanding its global manufacturing capacity with the construction of the new Hovione Tejo

Campus in Seixal, Portugal. The first construction phase of the Hovione Tejo Campus in Seixal has entered its final stage, with commissioning set for mid-2027. Spanning 42 hectares, the site will initially feature two production buildings, one for particle engineering technologies and one for final dosage forms. The operation of this site will dramatically expand its global manufacturing capabilities.

The company also recognizes that the Japanese market is a center of innovation and excellence in the pharmaceutical field and is committed to building sustainable partnerships that meet the needs of the Japanese market.

Regarding future developments, Yuken Kyoyama (General Manager, Japan) mentioned as follows:

“Driven by a culture of trust, reliability, and long-term investment, Hovione aims to continually elevate its scientific capabilities and customer-centric offerings in Japan. The company’s established global leadership in relevant pharmaceutical platforms, paired with its ability to deliver tailored, innovative solutions, positions Hovione to significantly contribute to the advancement of the pharmaceutical industry in Japan, aligning seamlessly with the high standards and expectations of its Japanese partners.”